Policy paper

Infected Blood Compensation Scheme Summary

Published 21 May 2024

The Prime Minister acknowledged the final Infected Blood Inquiry Report on 20 May 2024, apologising on behalf of the Government for the decades of suffering and injustice experienced by the victims of this scandal. You can read a transcript of the Prime Minister’s statement. 

No measures can or will ever fully compensate for the losses and hardships suffered. The Government has accepted the Inquiry’s recommendation to provide financial compensation to victims of infected blood. 

The Scheme will deliver financial compensation to victims of infected blood. The Scheme responds directly to and is in line with the recommendations made by the Infected Blood Inquiry in its second interim report, which considered the earlier study into compensation by Sir Robert Francis KC. The Scheme has also been informed by the advice of the Infected Blood Inquiry Response Expert Group. 

Wherever possible, the Scheme has been designed to be simple and to enable payments to be made with the minimum possible delay.

Purpose of this document

This document outlines the proposed Infected Blood Compensation Scheme - referred to throughout this document as ‘the Scheme’ - which will be delivered by a new independent arm’s length body, the Infected Blood Compensation Authority (IBCA). The proposed Scheme is subject to further validation with representatives of the infected blood community, prior to being established in regulations.

Note on language

The Government recognises the individuality of the experiences of all those impacted by infected blood and does not intend to minimise the hardship suffered by people across the UK through the language and terminology used in this document and other related guidance.

This document uses the term ‘victim(s)’ to refer collectively to anyone directly or indirectly impacted by infected blood who is eligible for compensation. In line with the language most commonly used throughout the Inquiry, the document refers to people infected with HIV, Hepatitis C or Hepatitis B as an ‘infected person’, and the associated family members and others who provided care for a person with an infection as an ‘affected person’.

Infected Blood Compensation Scheme: Overview

The Scheme is a government-funded scheme designed to provide financial compensation to victims of infected blood in the UK. 

Key information about the Scheme is summarised here, with further detail provided throughout this document:

• The Scheme will be open to both infected and affected persons.
• The Scheme will be UK-wide, operated by an independent arm’s length body called the Infected Blood Compensation Authority (IBCA).
• For the majority of applicants, tariffs will be used to calculate compensation. In defined circumstances, a bespoke assessment of individual needs by the IBCA will help to ensure the appropriate compensation is awarded.
• Compensation tariffs for the Scheme will be informed, but not limited, by current practice in UK courts and tribunals.
• The Scheme will have no immediate effect on payments made through the Infected Blood Support Schemes (IBSS). Payments will continue to be paid, at the same level, via the IBSS and on an ex-gratia basis until 31 March 2025. This means that any payments received before and up to 31 March 2025 will not be deducted from compensation awarded through the new Scheme.
• Any past or future interim compensation payments will be automatically deducted from the compensation awards made through the Scheme. 
• For people diagnosed with an eligible infection before 1 April 2025, the Scheme will remain open to applications for 6 years, until 31 March 2031. For people diagnosed after 1 April 2025, the Scheme will remain open to applications for 6 years from the person’s date of diagnosis.
• Accepting compensation through the Scheme will not remove any right a person has to pursue a claim in court.
• Compensation payments made to the infected and affected through the Scheme will not impact their eligibility for means tested benefits. See ‘Effect of other payments on compensation’ section for further detail.
• All compensation payments made through the Scheme will be exempt from tax.

Designing the Scheme

The proposed Scheme is based on the recommendations and principles put forward by the Infected Blood Inquiry. In line with these, the Government has sought to design a fair and comprehensive compensation scheme that will be quick and simple for eligible applicants to access. The priority will be to deliver compensation as swiftly as possible and with the minimum possible delay, as advised by Sir Brian Langstaff and the Inquiry.

The Scheme’s detailed design reflects the advice of the Infected Blood Inquiry Response Expert Group, chaired by Professor Sir Jonathan Montgomery. The Expert Group brought together legal and clinical experts who were assisted by care specialists. 

The Scheme accepts the Inquiry’s recommendations on eligibility for infected persons. For affected persons, the Scheme delivers on the spirit of the Inquiry’s recommendations on eligibility but has linked eligibility to familial relationship or their provision of care to the infected person. The Scheme includes the categories of award recommended by the Inquiry which are payable to all infected persons and most affected persons.

The proposed Scheme is subject to further validation with representatives of the infected blood community, prior to being established in regulations. This process will be led by the interim chair of the Infected Blood Compensation Authority, Sir Robert Francis. The Government will finalise the Scheme proposal and present it to Parliament for approval in secondary legislation. The Victims and Prisoners Bill sets a three month deadline for the making of these regulations.

Delivery

The Scheme will be administered by a new independent arm’s length body called the Infected Blood Compensation Authority (IBCA).

Eligibility

The Scheme will recognise and provide financial compensation to victims of infected blood, both people who have been infected and affected.  

The Scheme has been designed, in line with advice from the Expert Group, to minimise the burden on those applying. People registered on a current UK Infected Blood Support Scheme (IBSS) or who were in receipt of support payments from the Alliance House Organisation (AHO) schemes^{[footnote 1]} will therefore automatically be eligible and registered for the Scheme.

Infected persons

Infected persons include those directly and indirectly infected, which are defined as follows:

A person who is or was directly infected:

• with HIV through the use of NHS-supplied blood, blood products and/or tissue;
• with an acute or chronic case of Hepatitis C through the use of NHS-supplied blood, blood products and/or tissue;
• with a chronic case (more than 6 months) of Hepatitis B through the use of NHS-supplied blood, blood products and/or tissue;
• with an acute case (less than 6 months) of Hepatitis B through the use of NHS-supplied blood, blood products and/or tissue and died as a result of the Hepatitis B infection during the acute period.

or a person who is or was indirectly infected

• by transmission of infection from a person who is or was directly infected (e.g. a person infected by their partner);
• by transmission of infection, in defined circumstances, from another person who was infected by someone who was directly infected (e.g. a child infected by their mother who was infected by her partner).

Affected persons

Affected persons include those who have suffered the impacts of infected blood through their relationship with a living or deceased infected person (as described above). Affected persons include:

Partners of eligible infected persons. This includes:

• spouses;
• civil partners;
• partners cohabiting with an eligible infected person for at least one year following infection.

Partners who separated from the eligible infected person prior to infection will not be eligible for compensation.

Parents of an eligible infected person, including:

• biological parents;
• adoptive parents;
• others acting in the capacity of a parent as described below (e.g. step parents, grandparents);

who

cared for and lived with an eligible infected person whilst that person was under the age of 18. The provision of care and accommodation must have continued or been expected to continue for a period of at least 1 year. 

The age at which the child became infected is not relevant to eligibility but compensation rates will be higher for the parents of an infected person where the onset of infection began before the child turned 18 (and the parents cared for and lived with the infected child for at least 1 year) than for parents whose child was infected as an adult.

Children of an eligible infected person, including:

• biological children;
• adoptive children;
• others in the position of a child as described below (e.g. step children);

who

while under the age of 18, were cared for and lived with (for a period of at least 1 year) a parent who was, or later became, infected. 

The age of a child at the time of infection does not impact eligibility but compensation rates will be higher for children who, while under the age of 18, lived with and were cared for by an infected parent (for at least 1 year), than for people whose parents were infected when they were in adulthood.

Siblings of eligible infected persons, including:

• biological and adoptive siblings;
• step siblings;
• others in the position of a sibling (as described below);

who

while under the age of 18, lived in the same household as an infected person for a period of at least 2 years after the onset of the infection.

Carers of an eligible infected person (e.g. friends or family) who, without reward or remuneration, provided personal care or support greater than would otherwise reasonably have been expected. Such carers will be eligible for compensation in their own right where the provision of care averaged at least 16.5 hours of care per week over a time period of at least 6 months.

Estate applications

Where a person who would have been eligible to apply as an infected person has died, the personal representatives of the deceased person’s estate may apply for compensation under the Scheme on behalf of the estate of the deceased infected person. 

In line with the recommendation in the Infected Blood Inquiry’s second interim report, where an affected person has died it is not possible for the personal representatives of their estate to apply for compensation.

Multiple claims

Some people eligible to receive compensation through the Scheme may have been affected by their relationship with multiple infected persons. Other people may have themselves been infected and also affected by the infection of a loved one. In such circumstances, a person will be offered multiple injury awards to reflect the scale of their suffering and/or loss.

Compensation assessment and calculation

The Scheme will offer financial compensation outcomes informed, but not limited, by current practice in UK courts. 

In the majority of cases, compensation paid through the Scheme will be calculated in line with tariffs and based on the severity of infection and negative impacts suffered by victims in different aspects of their lives.

An overview of the method used to calculate compensation awarded through the Scheme is outlined below.

Tariff approach - Core and Supplementary Routes

Under the Scheme, a tariff-based framework will be used to calculate the amount of compensation payable to those eligible. In practice, this means that compensation will be calculated based on predetermined criteria and rates. Using a tariff approach will minimise the amount of information that applicants are required to provide (i.e. no detailed information relating to past earnings or past care will be required) and ensure that compensation is awarded in a fair and consistent way.

The tariffs for the Scheme have been informed by the advice of the Expert Group and are designed to be suitable for the majority of people applying. Where compensation awards are calculated using the tariff system alone, this is known as the Core Route. Once accepted onto the Scheme, the compensation due to a recipient will be calculated in the first instance via the Core Route process. 

Once accepted onto the Scheme, all eligible applicants will be offered an award under the Core Route. In exceptional cases, where an applicant can demonstrate that their circumstances necessitate compensation beyond that offered through the Core Route, a Supplementary Route will be available. The Supplementary Route may involve a personalised assessment or require the applicant to provide additional information to ensure that the compensation paid through the Scheme is appropriate to the individual’s specific circumstances. An assessment under the Supplementary Route would not delay the compensation offer made under the Core Route.

Examples of where the Supplementary Route may be required include: 

• cases where a person has faced or continues to face very high care costs due to secondary impacts of infection not otherwise covered by the Core Route (e.g. blindness);
• cases where a person was a high earner prior to infection and therefore suffered greater financial losses through lost income.

The Supplementary Route will have a limit on the highest level of award the Scheme can offer. Limits on awards will be published so applicants can see the highest levels of awards the Scheme can offer.

Compensation - Categories of Award

The Inquiry has highlighted the unique suffering that victims of the infected blood scandal have endured - this should be recognised in compensation. Under the Scheme, compensation will be calculated in line with the Categories of Award outlined in the table below. Each Category of Award recognises and compensates for the impacts of the infected blood scandal in different areas of a person’s life. This approach is in line with the ‘heads of award’ recommended by the Infected Blood Inquiry.

Compensation awarded will depend on whether an application is made for an infected or affected person, as shown in the table.

Category of Award	Description	Compensation paid to whom?
Injury award	This award recognises the physical and mental injury, emotional distress and injury to feelings that may have been caused or will in future be felt as a result of: Infected blood and/or related medical treatments; the death of an infected person; the likely death of a loved one in the future. Awarded using tariffs determined by infection severity and the affected person’s relationship to the infected person.	Infected and affected applicants
Social Impact award	This award recognises the past and future social consequences of the infection including stigma and social isolation.  Awarded using tariffs to acknowledge that the stigma suffered by both the infected and affected person is likely as a result of societal prejudice rather than knowledge of the clinical symptoms.	Infected and affected applicants
Autonomy award	This award provides additional redress for the distress and suffering caused by the impact of the disease, including interference with family and private life (e.g. loss of opportunity to have children).  This award also recognises the aggravated distress caused by interferences in the autonomy and private life of the eligible applicant. Awarded using tariffs to avoid intrusive questioning and re-traumatisation.	Infected and affected partner, parent and child applicants
Care award	This award recognises the past and future care needs and associated costs for infected persons. The award is dependent on individual circumstances, and calculated against a formula based on the typical pattern of care needs for each infection severity band. Acute infections are unlikely to have had the same ongoing care requirements as chronic infections. Proposed awards for acute infections are therefore lower, but higher care awards can be accessed where applicants can demonstrate higher care costs.	Infected applicants (or their estates) only.  Care awards can be paid directly to affected persons on the request of an infected person or their estate representative.
Financial Loss award	This award recognises the past and future financial losses suffered as a result of infection. This includes both financial loss and loss of services (e.g. providing childcare).  The award is dependent on individual circumstances and is calculated against a formula based on the likely impact of an infection and subsequent treatment on an infected person’s ability to work through disease progression.	Where an infected person is living, the Financial Loss award is paid to the infected person directly Where an infected person is deceased: an award for past financial loss (i.e. from the point of infection to death) is paid to the estate of the infected person; an award for future financial loss (i.e. years between death and healthy life expectancy age) is paid to any affected dependents.

Infection Severity Banding

Compensation awarded through the Scheme for infected persons will take into account the severity of infection suffered. Where a person has suffered the impact of co-infection (e.g. both HIV and Hepatitis C), this will also be taken into account in calculating compensation.

Infection severity banding for the Scheme has been designed in line with clinical diagnostic markers. This means that in most cases, applicants will know (or easily be able to identify from medical notes) the severity banding relevant to their application without needing to provide large volumes of medical evidence.

Indicative Infection Severity Bands are shown in the table below.

Indicative Infection Severity Bands	Notes on severity band definitions
Hepatitis B - Acute (where the infection resulted in a fatality in the acute period)	Acute infections are defined as an infection shorter than 6 months
Hepatitis C - Acute	Acute infections are defined as an infection shorter than 6 months.
Hepatitis C or Hepatitis B - Chronic	Chronic infections are defined as an infection longer than 6 months
Hepatitis C or Hepatitis B - Cirrhosis (liver damage)	Cirrhosis is serious scarring (fibrosis) of the liver caused by long-term liver damage
Hepatitis C or Hepatitis B - Decompensated cirrhosis and/or liver cancer and/or liver transplantation	Decompensated cirrhosis is characterised by the presence of hepatic encephalopathy (confusion due to liver damage) or ascites (accumulation of fluid in the abdomen) or variceal haemorrhage (bleeding from dilated veins in the gullet or stomach) or a Child-Pugh score greater than 7
HIV	Single severity banding
Co-infection of HIV and Hepatitis C or Hepatitis B	Co-infections severity bands will reflect the severity of the Hepatitis infection as described above and the HIV infection

Severity banding will be used to calculate compensation awards for infected persons. Those who are automatically accepted onto the Scheme as a beneficiary of one of the IBSS or AHO schemes may need to provide some additional information in order for the IBCA to determine their severity banding. Set tariff rates will be used for calculating awards relating to Injury, Social Impact and Autonomy, with a formula-based approach reflecting individual circumstances used for calculating Financial Loss and Care awards.

Severity banding will be used to calculate Injury awards for affected persons. Affected persons of an infected person with (i) Hepatitis C or Hepatitis B (Cirrhosis) or (ii) Hepatitis C or Hepatitis B (Decompensated cirrhosis and/or liver cancer and/or liver transplantation), or (iii) co-infections, or (iv) HIV or (v) Hepatitis B (Acute infection, where the infection resulted in a fatality in the acute period), will receive a higher Injury award to reflect the impact of the death or likely death of a loved one in the future.

Managing money received through compensation awards

The Government recognises that people awarded compensation through the Scheme may have different preferences for how they receive the money that is paid to them.

People receiving compensation through the Scheme will therefore be able to choose to receive their entitled awards either as:

• a single lump sum payment of the total compensation award; or
• a series of payments (instalments) over a fixed number of years, allowing recipients to receive a regular, predictable income over a given period.

Where the infected person has died, estate representatives will receive compensation as a single lump sum payment which can then be distributed to beneficiaries of the estate as appropriate. 

The IBCA will develop a financial advice and support service that will assist people awarded compensation with managing their compensation awards, accessing financial services, and accessing benefits advice where relevant.

Time limits for application

For people who are diagnosed before 1 April 2025, the Scheme will remain open to applications for compensation for 6 years from 1 April 2025 (until 31 March 2031). The proposed date for closing the Scheme to people with existing diagnoses will be reviewed within 3 years (by 31 March 2028) to ensure that it remains appropriate based on the numbers of applications and expected processing times.

For people who are diagnosed after 1 April 2025, the Scheme will remain open to applicants for 6 years from their date of diagnosis.

Infected Blood Support Scheme (IBSS) payments

The Scheme will compensate for both past and future losses suffered as a result of infected blood. This will mean that, for the first time, payments to those who have suffered as a result of infected blood will be on a single statutory basis that applies across the UK. 

The establishment of the Scheme will not have any immediate impact on the support payments received through the IBSS. The eligibility criteria for the IBSS will not be impacted by the new Scheme.

IBSS are delivered separately in England, Wales, Scotland and Northern Ireland and decisions on individual schemes will be for the devolved administrations.

Payments will continue to be paid, at the same level, via the IBSS and on an ex-gratia basis until 31 March 2025. This means that any payments received before and up to 31 March 2025 will not be deducted from compensation awarded through the new Scheme. After this point, from 1 April 2025, people who receive IBSS payments will continue to receive payments until such time that their case is assessed under the new Scheme by the Infected Blood Compensation Authority (IBCA). Once assessed under the Scheme, the applicant will be able to choose how to receive their compensation (lump sum or periodic payments). 

The IBCA will not be able to assess all cases at the same time. Therefore, to ensure a fair and consistent approach over the transition from the IBSS to the new Scheme, any IBSS payments received from 1 April 2025 will be deducted from a person’s total compensation award.

In the event that the IBCA assesses that a person is entitled to less compensation through the Scheme than would have otherwise been paid to them through continued IBSS support payments, an additional top-up payment will be provided to bring the compensation they receive up to the level of the support payments. This will ensure that no one will receive less compensation through the Scheme than the payments they would have otherwise been entitled to through existing schemes. Any top-up payment awarded will take into account other compensation payments that a person has received through the Scheme, either in their own right or as an estate beneficiary.

Effect of other payments on compensation awarded under the Scheme

Infected Blood Support Schemes and Alliance House Organisation Schemes

The Scheme is separate from the existing UK Infected Blood Support Schemes (IBSS). Any ex-gratia support or payments received through the IBSS or earlier AHO schemes^{[footnote 2]} before 1 April 2025, will not be deducted from compensation paid through the Scheme.

Interim Compensation Payments

Where applicants to the Scheme have previously received interim compensation payments, these will be automatically deducted from the compensation award paid through the Scheme.

Other compensation awards

Any other past compensation awards received (e.g. those made by a court or tribunal) will be deducted from compensation awards through the Scheme.

Should a person choose to pursue litigation after receiving compensation through the Scheme, compensation amounts previously awarded through the Scheme should be deducted from any awards made through the courts.

Taxation

Compensation payments made under the Scheme will be exempt from income tax, capital gains tax and inheritance tax. This is in line with tax exemptions for the first and second interim payments.

Means tested benefits

Compensation payments made through the Scheme will not adversely impact means tested benefits received by persons who are either infected or affected.

Where compensation payments are awarded to an estate and are received by estate beneficiaries on distribution of the estate, this will not impact the recipient’s eligibility for means tested benefits if they meet the criteria of an affected person for payments in their own right under the Scheme.

Appeals

Should an applicant be dissatisfied with the outcome of their application to the Scheme, they will have the right to a review and the right to an appeal. The applicant must exercise their right to review and receive a decision under the IBCA internal review process before submitting their appeal application. If a person is dissatisfied with the outcome of the internal review, they will be able to appeal the decision through a First-tier Tribunal, administered by the HM Courts and Tribunals Service.

Rights to litigation

The Government hopes that the Scheme will enable victims of infected blood to receive due compensation without the need to go through a court or tribunal process to seek redress. 

Accepting compensation under the Scheme will not, however, remove  any right an eligible applicant might have to seek to  pursue litigation. This aligns with the recommendation made by the Infected Blood Inquiry. 

Should a person choose to pursue litigation, we would expect any compensation awarded through the Scheme to be deducted from compensation awarded through the courts.

Illustrative Tables

Proposed awards for people who are infected

The proposed ‘Core Route’ tariff structure has been informed by the work of the Expert Group and uses a flat rate tariff or simple standard formula to calculate each category of award. The tariffs have been designed to be appropriate for the majority of applicants. Under the Core Route, flat rate tariffs are used to calculate Injury, Social Impact and Autonomy Awards. A standard formula is used to calculate Financial loss and Care awards, meaning that individual circumstances are taken into account in calculating the compensation awarded. 

The below tables are intended to give an illustration of the compensation award that an infected person living with a single infection or co-infection may expect to receive. Care awards and Financial Loss awards are calculated using a formula, based on individual circumstances. For this reason, the rates provided in the table below are illustrative, and show an estimated range for the award that the majority of eligible people within this cohort are likely to receive through the Core Route.

The awards shown should not be taken as an accurate calculation of the total compensation award for all eligible persons within this cohort. The range listed is an illustration of what the majority of people who are infected could receive - it is not the minimum to maximum award range. Some people may be eligible for additional compensation, depending on individual circumstances, via the Supplementary Route.

The proposed Scheme is subject to further validation with representatives of the infected blood community prior to being established in regulations. This will be led by the interim chair of the Infected Blood Compensation Authority, Sir Robert Francis, with final Scheme proposals to be made by ministers and presented to Parliament for approval in secondary legislation. The duration of the exercise will necessarily be limited by the 3 month deadline for making regulations outlined in the Victims and Prisoners Bill. This will ensure that whilst proposals are validated with the infected blood community, there will be no unnecessary delay to paying compensation to people who are infected and affected.

Illustrative awards for a living infected person with a single or monoinfection

	Total award across all Categories of award+
Hepatitis C (Acute)	£35,500
Hepatitis C or Hepatitis B (Chronic)	£665,000 - £810,000
Hepatitis C or Hepatitis B (Cirrhosis)	£985,000 - £1,130,000
Hepatitis C or Hepatitis B (Decompensated cirrhosis, and/or liver cancer and/or liver transplantation)	£1,412,000 - £1,557,000
HIV	£2,225,000 - £2,615,000

+This table shows illustrative Core Route awards for people living with an infection. The range listed here is our estimate of what the majority of people who are infected will receive - it is not the minimum to maximum award. Applicants will also have the option of applying for an award under the Supplementary Route if they can demonstrate their costs are greater.

Illustrative awards for a living infected person with a co-infection

	Total award across all Categories of award+
HIV and Hepatitis C/ Hepatitis B (Acute)	£2,257,500 - £2,647,500
HIV and Hepatitis C/ Hepatitis B (Chronic)	£2,270,000 - £2,660,000
HIV and Hepatitis C/ Hepatitis B (Cirrhosis)	£2,315,000 - £2,705,000
HIV and Hepatitis C/ Hepatitis B  (Decompensated cirrhosis)	£2,345,000 - £2,735,000
HIV and Hepatitis C/ Hepatitis B (liver cancer and/or liver transplantation)	£2,345,000 - £2,735,000
Hepatitis C and Hepatitis B (Chronic)	£730,000 - £1,642,000 (Depending on severity band)

+This table shows illustrative Core Route awards for people living with a co-infection. The range listed here is our estimate of what the majority of people who are infected will receive - it is not the minimum to maximum award. Applicants will also have the option of applying for a Supplementary Route if they can demonstrate their costs are greater.

Proposed awards for people who are affected 

The table below is intended to give an illustration of the compensation that people who are affected might expect to receive against each category of award.

Awards to affected persons will vary depending on: the infection severity banding of the infected person to whom the claim relates (Injury award); the relationship between the affected and infected person (Autonomy award); whether or not the infected person is deceased (Financial loss award); and, whether or not the infected person or their estate representative nominates the affected person to receive the payment (Care award).

Scroll right to left to view the full contents of the table.

Category of Award	Partner	Parent (where onset of child’s infection began before age 18)	Child  (where onset of parent’s infection began before child turned 18)	Siblings	Carers; Parent (where onset of child’s infection began after age 18); Child (where onset of parent’s infection began after child turned 18)
Hepatitis B Acute (where the infection resulted in a fatality in the acute period) or Hepatitis C/ Hepatitis B (Cirrhosis)  or Hepatitis C/ Hepatitis B (Decompensated cirrhosis)  or HIV  or co-infection Total award for Injury, Social Impact and Autonomy Categories of award	£110,000	£80,000	£55,000	£30,000	£30,000
Hepatitis C/ Hepatitis B (Chronic) Total award for Injury, Social Impact and Autonomy Categories of award	£58,000	£34,600	£34,600	£28,000	£28,000
Bereaved affected where dependent on infected person at time of death Financial Loss award	Available for bereaved affected persons, dependent on circumstances* £16,682 per  annum where applicable*	Available for bereaved affected persons, dependent on circumstances*	Available for bereaved affected persons, dependent on circumstances* £5,561- £22,243 per annum where applicable*	Available for bereaved affected persons, dependent on circumstances*	Available for bereaved affected persons, dependent on circumstances*
All affected persons Care Award	If nominated*	If nominated*	If nominated*	If nominated*	If nominated*

*see section below

Note on Financial Loss awards for people who are affected

Where the infected person is living: Past and future financial loss is paid to the person who is infected, either in a lump sum or periodical payments.

Where the infected person is deceased: Past financial loss from the point of infection to death is paid to the estates of the deceased person. Financial loss from the point of death to the estimated healthy life expectancy age of the deceased is paid to the affected dependents registered with the Scheme. 

Proposed tariff rates for Financial Loss awards to bereaved affected persons, dependent on circumstances:

• Partner of an infected person at time of death: £16,682 per annum.
• Child under 18 at the time of the infected person’s death: £5,561 per annum until the age of 18. 
• Child under 18 who has lost both parents to infected blood related infections:  £22,243 per annum until the age of 18. 
• Other affected persons could claim dependency on the provision of evidence via the Supplementary Route. This would include where dependency of a child goes beyond the age of 18 (e.g. in the case of a child with a disability)

Note on Care awards for people who are affected

Care awards are paid directly to infected persons (or their estates). Care awards can be paid directly to affected persons on the request of an infected person or their estate representative.

1. The Macfarlane Trusts, the Eileen Trust, the Skipton Fund, the Caxton Foundation and MFET Ltd ↩

2. The Macfarlane Trust, the Eileen Trust, the Skipton Fund, the Caxton Foundation and MFET Ltd ↩